SCHEMBL7033588

SCHEMBL7033588

Cc1ccccc1C(=S)c1ccc(Nc2ccncc2)cc1Cl

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 10/20 0.57
MAPK13 O15264 9/20 0.57
MAPK12 P53778 9/20 0.57
MAPK11 Q15759 9/20 0.57
TYK2 P29597 3/20 0.45
SMN1; SMN2 Q16637 2/20 0.40
GRM4 Q14833 1/20 0.40
ALDH1A1 P00352 1/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
CCNA2 P20248 1/20 0.39
CDK2 P24941 1/20 0.39
DHODH Q02127 1/20 0.39
JAK2 O60674 1/20 0.39
MAPT P10636 2/20 0.39
KDM4E B2RXH2 1/20 0.39
HTT P42858 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
RAB9A P51151 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7036690 0.91 MAPK14 (0.49) MAPK14MAPK13MAPK12MAPK11TYK2
SCHEMBL1901734 0.89 MAPK14 (0.71) MAPK14MAPK13MAPK12MAPK11SMN1; SMN2
SCHEMBL1899616 0.88 MAPK14 (0.61) MAPK14MAPK13MAPK12MAPK11SMN1; SMN2
SCHEMBL7040292 0.86 MAPK14 (0.54) MAPK14MAPK13MAPK12MAPK11ALDH1A1
SCHEMBL7040238 0.86 MAPK14 (0.53) MAPK14MAPK13MAPK12MAPK11SMN1; SMN2
SCHEMBL1907237 0.86 MAPK14 (0.59) MAPK14MAPK13MAPK12MAPK11SMN1; SMN2
SCHEMBL5173361 0.86 MAPK14 (0.62) MAPK14MAPK13MAPK12MAPK11SMN1; SMN2
SCHEMBL7030742 0.85 MAPK14 (0.55) MAPK14MAPK13MAPK12MAPK11GRM4
SCHEMBL7034867 0.85 MAPK14 (0.81) MAPK14MAPK13MAPK12MAPK11TYK2
SCHEMBL7033514 0.85 MAPK14 (0.51) MAPK14MAPK13MAPK12MAPK11SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6432962-B2 Benzophenones as inhibitors of IL-1β and TNF-α LEO PHARMACEUTICAL PRODUCTS LTD. A/S (DK) 2002-08-13 US claimed
EP-1289958-A2 BENZOPHENONES AS INHIBITORS OF IL-1$g(b) AND TNF-$g(a) Leo Pharma A/S (DK) 2003-03-12 EP disclosed
US-6432962-B2 Benzophenones as inhibitors of IL-1β and TNF-α LEO PHARMACEUTICAL PRODUCTS LTD. A/S (DK) 2002-08-13 US disclosed
US-20020016347-A1 Benzophenones as inhibitors of IL-1beta and TNF-alpha LEO PHARMACEUTICAL PRODUCTS LTD. A/S (DK) 2002-02-07 US disclosed
WO-2001090074-A2 BENZOPHENONES AS INHIBITORS OF IL-1β AND TNF-$g(a) LEO PHARMA A/S (DK) 2001-11-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020016347-A1 Benzophenones as inhibitors of IL-1beta and TNF-alpha IL1B, IL1A, NFKBIA MAPK14 625/4885MAPK13 1908/4885MAPK12 1184/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.